PSA assay-specific artificial neural networks

PSA assay-specific artificial neural networks
	Use of artificial neural networks (ANNs, Program ProstataClass ) show an improved discrimination between prostate cancer (PCa) and benign prostate hyperplasia (BPH) with inclusion of PSA, percent free PSA (%fPSA) and additional clinical data like age, prostate volume and status of digital rectal examination. In a comparison of an IMMULITE PSA-based ANN (iANN) with newly PSA assay-adapted ANNs (nANNs) in 5 different populations in a total of 4480 patients within the PSA range 2-10 ng/mL the ProstataClass-ANN could enhance specificity in 2/3 of all cases compared to %fPSA. However, the newly PSA assay-adapted ANNs enhanced specificity in all cases. In parallel measurements of 5 different PSA assays in 800 patients we found differences in %fPSA up to 10% which is relevant. Currently the development of an ANN program for use with different PSA assays is underway.
Head of Project:
	Prof.Dr.sc.med. Klaus Jung Charité - Universitätsmedizin Berlin Department of Urology Department of Urology CCM Tel. 450-515041 Fax 450-515904 klaus.jung@charite.de
Additional Head of Project:
	Dr. Carsten Stephan
Additional Member of Project:
	PD Dr. Lein, Prof. Schnorr,
Begin/End of Project:
	09/2005 - 08/2008
Funded by:
	Monika Kutzner Stiftung
Publications:
	1. Stephan C, Cammann H, Semjonow A, Diamandis EP, Wymenga LFA, Lein M, Sinha P, Loening SA, Jung K. Multicenter evaluation of an artificial neural network to increase prostate cancer detection rate and reduce unnecessary biopsies. Clin Chem 2002;48:1279-87. 2. Stephan C, Cammann H, Jung K. Artificial neural networks: has the time come for their use in prostate cancer patients? Nat Clin Pract Urol 2005;2:262-3. 3. Stephan C, Jung K, Soosaipillai A, Yousef GM, Cammann H, Meyer H, Xu C, Diamandis EP. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection. BJU Int 2005;96:521-7. 4. Stephan C, Klaas M, Müller C, Schnorr D, Loening SA, Jung K. Interchangeability of measurements of total and free prostate-specific antigen in serum with five frequently used assay combinations: an update. Clin Chem 2005;accepted, October 10, 2005. 5. Stephan C, Xu C, Brown DA, Breit SN, Michael A, Nakamura T, Diamandis EP, Meyer H, Cammann H, Jung K. Three new serum markers for prostate cancer detection within a percent free PSA based artificial neural network. Prostate 2005;accepted, October 17, 2005.